<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03535727</url>
  </required_header>
  <id_info>
    <org_study_id>J1847</org_study_id>
    <secondary_id>IRB001676646</secondary_id>
    <nct_id>NCT03535727</nct_id>
  </id_info>
  <brief_title>A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical activity of gemcitabine,
      nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with metastatic
      pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Percentage of participants experiencing toxicities</measure>
    <time_frame>4 years</time_frame>
    <description>Percentage of participants by grade of toxicity as defined by CTCAE version 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Progression Free Survival (PFS)</measure>
    <time_frame>4 years</time_frame>
    <description>Duration of time (months) from start of treatment to time of first documented progression or death, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Response Rate (RR)</measure>
    <time_frame>4 years</time_frame>
    <description>Percentage of patients who achieved complete response (CR) or partial response (PR) among all evaluable patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Disease Control Rate (DCR)</measure>
    <time_frame>4 years</time_frame>
    <description>Percentage of patients who achieved complete response (CR), partial response (PR), or stable disease (SD) among all evaluable patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Overall survival (OS)</measure>
    <time_frame>4 years</time_frame>
    <description>Duration of time (months) from start of treatment to time of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of participants experiencing toxicities with GAX-CI (gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan, a combinatorial therapy).</measure>
    <time_frame>4 years</time_frame>
    <description>Percentage of participants by grade of toxicity as defined by CTCAE version 5.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Adenocarcinoma</condition>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Neoplasm, Glandular</condition>
  <condition>Neoplasms</condition>
  <condition>Neoplasms Pancreatic</condition>
  <condition>Digestive System Neoplasm</condition>
  <condition>Endocrine Gland Neoplasms</condition>
  <condition>Digestive System Disease</condition>
  <condition>Pancreatic Diseases</condition>
  <condition>Endocrine System Diseases</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(28 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(21 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>IV over 30 minutes; Days 1 and 15</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>IV over 30 minutes; Days 1 and 15</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>PO twice daily (BID); Days 1-7, 15-21</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV over 60 minutes; Days 1 and 15</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>IV over 30 minutes; Days 1 and 15</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>IV over 30 minutes; Days 4 and 11</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>IV over 30 minutes; Days 4 and 11</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>PO BID; Days 1- 14</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV over 60 minutes; Days 4 and 11</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>IV over 30 minutes; Days 4 and 11</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Camptosar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have histologically or cytologically confirmed untreated metastatic pancreatic
             adenocarcinoma.

          -  Patients with the presence of at least one measurable lesion.

          -  Male or non-pregnant and non-lactating female of age &gt;18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  Patients must have adequate organ and marrow function defined by study-specified
             laboratory tests.

          -  Must use acceptable form of birth control while on study.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Patients who will be considered for surgery are ineligible.

          -  Patient who have had any prior chemotherapy within 5 years of enrollment.

          -  Patient who have had radiotherapy for pancreatic cancer.

          -  Age â‰¥ 76 years

          -  Patient who is receiving or have received any other investigational agents within 28
             days prior to Day 1 of treatment in this study.

          -  Patient who has undergone major surgery, other than diagnostic surgery within 28 days
             prior to Day 1 of treatment in this study.

          -  Patient who has known brain metastases.

          -  Patient with history of hypersensitivity or allergic reactions attributed to compounds
             of similar chemical or biologic composition to gemcitabine, nab-paclitaxel,
             capecitabine, cisplatin, or irinotecan.

          -  Patient with uncontrolled intercurrent illness including, but not limited to,
             uncontrolled infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

          -  Patient who has serious medical risk factors involving any of the major organ systems.

          -  Patient who has known history of infection with HIV, hepatitis B, or hepatitis C.

          -  Pregnant or breast feeding.

          -  Patient is unwilling or unable to comply with study procedures

          -  Patient with clinically significant wound.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dung Le, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Institution</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
    <phone>4106143644</phone>
    <email>Sartosu@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Zorzi, RN</last_name>
    <phone>4106145818</phone>
    <email>Jzorzi1@jhmi.edu</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

